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Sir,
We read with interest the article by Bell et al (2006) that
reviewed the quality of the methodology in cancer pain clinical
trials. It has also been our experience that the methodology
employed in these trials has frequently been less than optimal. To
further quantify this problem, we undertook a systematic
qualitative review that specifically explored the pain assessment
methods used in oncological clinical trials (Caraceni et al, 2005)
and reached similar conclusions to those of Bell and colleagues.
For our review, we examined 68 journal articles published
between 1999 and 2002 that had chronic cancer pain as the
primary or secondary objective of a controlled clinical trial. Only
57% of these studies reported on the clinical characteristics of the
cancer pain, and in 81% pain pathophysiology was not mentioned.
More specifically, regarding the use of pain assessment methods,
we observed that:
 10% of the studies used nonvalidated pain measurement
methods;
 70% did not state the time frame over which the pain experience
was assessed;
 the method of administration (e.g. self-administered or external
observer interview) of the pain measurement tool was not
described in 46% of studies;
 a clear definition of the pain outcome measure was missing in
40% of studies;
 compliance with pain assessment was reported in only one of
the studies;
 only 25% of the studies gave a detailed description of the
missing data, another 44% provided a rough description of the
technique employed to deal with such data, and 31% made no
mention of this problem at all.
Our review concluded with a number of recommendations that
we believe will enable researchers and clinicians to approach this
field of study with more consistency and rigor – through an
enhanced understanding of how to choose, implement, analyse and
report pain measurement methods and data in oncology clinical
trials.
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